Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
Cangrelor
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
B01AC27
|
| gptkbp:CASNumber |
gptkb:163706-06-7
|
| gptkbp:developedBy |
gptkb:The_Medicines_Company
|
| gptkbp:hasMolecularFormula |
C17H25F3N5Na4O15P3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cangrelor tetrasodium
|
| gptkbp:indication |
patients undergoing percutaneous coronary intervention
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
P2Y12 receptor antagonist
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
DB06448 16220127 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
bleeding
dyspnea hypersensitivity reactions |
| gptkbp:UNII |
K8I9V0458D
|
| gptkbp:usedFor |
prevention of thrombotic events
|
| gptkbp:bfsParent |
gptkb:cangrelor
|
| gptkbp:bfsLayer |
7
|